Zoonotic Chlamydia caviae Tied to Community-Acquired Pneumonia

Share this content:
Zoonotic <i>Chlamydia caviae</i> Tied to Community-Acquired Pneumonia
Zoonotic Chlamydia caviae Tied to Community-Acquired Pneumonia

FRIDAY, Sept. 8, 2017 (HealthDay News) -- Three cases of community-acquired pneumonia involving Chlamydia caviae after exposure to ill guinea pigs have been described, according to a research letter published online Sept. 6 in the New England Journal of Medicine.

Bart P. Ramakers, M.D., Ph.D., from Bernhoven in the Netherlands, and colleagues described three unrelated cases of infection in otherwise healthy adults in their early 30s who had respiratory failure caused by severe community-acquired pneumonia after exposure to ill guinea pigs.

The researchers found that the three cases appeared over a period of about three years and occurred in individuals from different families, at different hospitals, and in different geographic areas. All three patients had chlamydia DNA detected in specimens obtained from the respiratory tract, serum, or both; the species was identified as C. caviae. There were no other causes of community-acquired pneumonia detected. All three of the patients recovered after being treated with doxycycline; however, in accordance with local protocols, different antibiotics regimens were used to treat the patients. In one case, the sequences of ompA and the single variable-number tandem-repeat region were identical in the bronchoalveolar lavage fluid from the patient and her guinea pig.

"Both veterinarians and physicians should be aware of the zoonotic potential of C. caviae. Although the extent to which C. caviae actually contributes to community-acquired pneumonia is unclear, awareness may help to clarify this issue," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »